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Abstract We aimed to immunohistochemically examine
the expression of KIT (CD 117) in human posterior uveal
melanoma and to analyze KIT-positive tumors for gene
mutations. Brought into a tissue microarray (TMA)
format were 101 formalin-fixed, paraffin-embedded pos-
terior uveal melanomas. Immunhistochemistry was per-
formed using the polyclonal anti-CD117 antibody from
Dako (A4502). In ten selected KIT-positive tumors, exons
2, 8, 9, 11, 13 and 17 were sequenced. Of the 101 cases,
89 (88%) could be evaluated on the TMAs. Immunohis-
tochemistry for CD 117 was weakly positive in 5 cases
(6%), moderately positive in 10 cases (12%) and strongly
positive in 57 cases (69%). No KIT mutations were
detected in the analyzed exons. In conclusion, human
posterior uveal melanoma frequently expresses CD117 at
high levels. Although KIT mutations could not be found,
it appears justified to investigate the utility of imatinib
mesylate in the treatment of these patients.
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Introduction
Although posterior uveal melanoma is the most common
primary intraocular malignancy, the neoplasm is rare,
with an overall incidence of 0.1–1.5. Its frequency
increases with advanced age. The average age of detec-
tion of posterior uveal melanoma ranges between 55 years
and 60 years [19]. The tumor has not only the capacity to
destroy vision, but can also metastasize and cause death.
In recent years, a marked progress in local tumor control
was achieved using therapeutic options such as enucle-
ation, radiation, photocoagulation, microsurgical resec-
tion or transpupillary thermotherapy [19]. However, none
of these treatments can prevent metastases. Therefore, the
prognosis of locally treated posterior uveal melanoma has
not changed during recent years. The metastatic rate of
the malignant uveal melanoma is about 35% at 10 years.
Results of systemic treatment for metastatic uveal mel-
anoma are still discouraging.
It is hoped that novel adjuvant cancer drugs targeting
specific gene products in cancer cells, such as imatinib
mesylate (STI 571; Glivec), will improve the success of
systemic therapy in uveal melanoma and other tumor
entities. Imatinib mesylate is a small molecule that
specifically inhibits several kinases, including ABL,
KIT (CD117) and platelet derived growth factor receptor.
Imatinib mesylate is of special interest in melanomas
because melanocytes are known to express at least one of
its molecular targets (KIT). KIT is a transmembrane
tyrosine kinase and acts as a type-III receptor for mast cell
growth factor or stem cell factor. KIT expression has been
described in various tumor entities [1, 7, 12, 14, 23].
Remarkably, metastatic and/or advanced gastrointestinal
stroma tumors (GIST), the tumor entities with the highest
KIT expression, responded well to imatinib mesylate
therapy in initial studies [4, 24]. There is hope that
imatinib mesylate might also be effective in other KIT-
expressing tumor entities. Several clinical studies are
currently investigating the effect of imatinib mesylate on
KIT-positive tumors of various sites, such as gliomas, soft
tissue sarcomas/bone sarcomas, ovarian cancers, primary
peritoneal cancers, pediatric solid tumors and colorectal
cancers [16].
As far as melanomas are concerned, only skin
melanomas have been analyzed for KIT expression.
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These studies have indicated a frequency of KIT expres-
sion ranging between 20% and 90% [1, 7, 23]. Uveal
melanoma has not been examined for KIT expression up
to now. To investigate the importance of KIT as a
potential therapeutic target in uveal melanomas, we
analyzed KIT expression in a series of 101 uveal
melanomas using the tissue microarray (TMA) technique
[2, 3]. In addition, we sequenced exons 2, 8, 9, 11, 13 and
17 in a subset of KIT-expressing tumors to identify
possible mechanisms of KIT activation in uveal melano-
ma.
Materials and methods
Tumors, TMA construction
Formalin-fixed, paraffin-embedded tissue material from 101 pos-
terior uveal melanomas from the years 1985–2002 were collected
from the archives of the Institute of Ophthalmopathology and
Pathology, University of Basel. All cases were classified according
to the pTNM classification [UJCC 5th edition, 1997]. The series
included 44 males and 57 females. The mean age was 79 years
(range 39–98 years). The pT stage was pT1a in 3, pT1b in 1, pT2a
in 25, pT2b in 27, pT2c in 6, pT3 in 15 and pT4 in 20 cases. pT
stage could not be determined in four cases. Histologically, a
spindle cell type was present in 50 cases, an epitheloid type in 13
cases and a mixed type in 38 cases. The construction of TMAs was
done exactly as described [2, 3]. In brief, tissue cylinders with a
diameter of 0.6 mm were taken from representative tumor areas of
each “donor” tissue block using a robotic precision instrument and
brought into a recipient paraffin block. Sections 4-mm thick of the
resulting TMA blocks were transferred to an adhesive coated slide
system (Instrumedics Inc., Hackensack, New Jersey).
Immunohistochemistry
Immunhistochemistry was performed using the polyclonal anti-
CD117 antibody A4502 (Dako, Glostrup, Denmark). In a compar-
ison of different commercially available anti-CD117 antibodies,
A4502 yielded the highest specificity and the least background
(unpublished data). A4502 was applied at a dilution of 1:300 at 4C
for 18 h, after 3 min pressure cooking in 10 mM sodium citrate
buffer (pH 6.0) for antigen retrieval. Endogenous peroxidase was
blocked using 0.3% hydrogen peroxidase diluted in methanol for
30 min. A standard avidin-biotin complex (ABC) technique (Vector
ABC kit) using diaminobenzidine for visualization was used. For
specificity control, a preabsorption of the antibody was performed
(CD117 peptide stock solution; Neomarkers PP1518). This antigen
matches the sequence of the epitope recognized by the polyclonal
antibody of Dako. A case of KIT-positive GIST was used for
control. The percentage of positive cells was estimated and the
staining intensity was semi-quantitatively recorded as 1+, 2+ or 3+.
For statistical analyses, the staining results were categorized into
four groups. Tumors without any staining were considered
negative. Tumors with 1+ staining intensity in less than 60% of
cells and 2+ intensity in less than 30% of cells were considered
weakly positive. Tumors with 1+ staining intensity in 60% of cells
or more, 2+ intensity in 30% or more up to 80% (not inclusive) or
3+ intensity in less than 30% were considered moderately positive.
Tumors with 2+ intensity in 80% or more or 3+ intensity in 30% or
more of cells were considered strongly positive.
Sequence analysis
Ten melanomas showing intense CD117 staining were selected for
KIT mutation analysis. Deparaffinizing of the formalin-fixed
tissues and DNA extraction was performed using a commercial
DNA extraction kit (Qia Amp DNA minkit, cat. #51304, Qiagen
GmbH, Hilden, Germany). Exons 2, 8, 9, 11, 13 and 17 were
amplified using a semi-nested polymerase chain reaction approach
[10] and were sequenced using the Big Dye Terminators Cycle
Sequencing Ready Reaction Kit (Applied Biosystems, Foster City,
CA, USA). Sequence products were analyzed on an ABI Prism 310
Genetic Analyzer (Applied Biosystems; Foster City, CA, USA).
Statistical analysis
Statistical analyses were performed using the statistical package
StatView 5.0 (Abacus Concepts, Berkley, CA). The chi-square
statistic was used for frequency comparisons of nominal catego-
rized variables. In the case of 22 contingency tables, significances
were calculated using Fisher’s exact test.
Results
Immunohistochemistry
Immunohistochemistry was interpretable in 89 of 101
cases (88%). Analysis failures were due to either lack of
tissue on the TMA section or a lack of vital tumor cells in
the arrayed samples. A positive CD 117 staining was seen
in 72 of 83 interpretable tumors (87%). The staining was
membranous in all cases (Fig. 1). Positivity was weak in 5
cases (6%), moderate in 10 cases (12%) and strong in 57
cases (69%). Examples of positive and negative staining
for CD 117 are shown in Fig. 2. There was no difference
in frequency or intensity of KIT staining between males
and females or between tumors of different stages or
different tumor cell types.
Mutation analysis
Sequence alterations of exons 2, 8, 9, 11, 13 and 17 were
not detected in any of the ten analyzed tumors.
Fig. 1 Example of a CD 117-positive tumor (magnification 100)
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Discussion
A TMA was used to evaluate the expression frequency of
KIT in a series of clinically well-documented 101 uveal
melanomas. Using this method, minute tissue samples
(diameter 0.6 mm) are analyzed on one microscope glass
slide. It is likely that focal alterations in gene expression
are not always detected in a TMA setting. However, this
perceived disadvantage seems to be compensated by a
maximal standardization of the analysis (where all
samples are processed under identical conditions) and
the high number of tumors that can be included in a TMA
study. Numerous studies have shown that representative
information can be obtained in TMA analyses [9, 17, 20,
21, 22] (Went et al., personal communication). For
example, the known frequencies of amplifications of
various genes were confirmed in TMA studies in various
tumor types [9, 18]. Other TMA projects confirmed the
previously established prognostic impact of molecular
markers such as the expression of estrogen receptor,
progesterone receptor and p53 in breast cancer [22] or of
the Ki67-labeling index in bladder cancer [15].
The results of this study show that KIT is frequently
expressed in uveal melanoma. More than 81% of our
tumors were KIT positive. Although it is difficult to
compare immunohistochemical studies if different anti-
bodies, staining conditions and scoring procedures are
applied, these data suggest that KIT expression is more
frequent in uveal than in skin melanoma. Such a high
frequency of KIT expression in uveal melanoma raises the
possibility that imatinib mesylate could be a therapeutic
option in these tumors. Imatinib mesylate was initially
designed to inhibit the bcr/abl fusion protein in chronic
myeloid leukemia, for which it was FDA approved in
May 2001 [5]. Later it was shown that imatinib mesylate
is also effective in KIT-positive GIST [24]. Several
studies are now ongoing to assess whether imatinib
mesylate has a beneficial effect on other KIT-positive
tumors [16].
Our data suggest that uveal melanoma is one of the
tumors with the highest frequency of immunohistochem-
ically detectable KIT expression. This could make uveal
melanoma a prime candidate for imatinib mesylate
therapy. However, c-KIT protein is also expressed in
normal melanocytes, and there is evidence that its
expression is downregulated or even lost in skin melano-
ma [13]. It is therefore possible that KIT expression in
uveal melanoma does not reflect “overexpression” but
rather represents preservation of normal protein expres-
sion. The lack of mutations in all ten tumors sequenced
for exons 2, 8, 9, 11, 13 and 17 also does not provide
evidence for presence of KIT alterations in uveal
melanoma. It has recently been shown that the response
rate to imatinib mesylate may depend on presence and
type of KIT mutation in a tumor [8]. If this is true in
general, the likelihood of uveal melanomas responding
favorably to imatinib mesylate may be low. However,
other authors have reported at least some therapeutic
effect in KIT-positive tumors expressing wild-type pro-
tein [6, 11].
Taken together, our data show that posterior uveal
melanoma is one of the most frequently KIT-positive
tumor entities. Although this seems to reflect preservation
of “normal level KIT expression” in melanocytes rather
than KIT mutations, these data may justify investigating
possible beneficial effects of imatinib mesylate in uveal
melanoma.
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